Form 4: Tourmaline Bio Director Sapna Srivastava Acquires Stock Options

Director Sapna Srivastava acquired stock options for 10,000 shares of Tourmaline Bio, Inc. at an exercise price of $13.91 on June 5, 2024.

Summary

• On June 5, 2024, Sapna Srivastava, a director of Tourmaline Bio, Inc., acquired stock options for 10,000 shares.
• The exercise price of these options is $13.91 per share.
• The options vest on the earlier of the anniversary of the transaction date or the date of the Issuer's 2025 Annual Meeting of Stockholders, contingent upon continued service.
• Following the transaction, Srivastava directly owns derivative securities for 10,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a standard insider transaction. The acquisition of options could be seen as a positive signal, but it's a routine filing.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This filing indicates a transaction by a director of Tourmaline Bio.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates